A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard o...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Anna V. Tinker, Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M. Oza
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2022-06-01
Seri Bilgileri:	Current Oncology
Konular:	epithelial ovarian cancer PARP inhibitors BRCA homologous recombination repair
Online Erişim:	https://www.mdpi.com/1718-7729/29/6/348
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!